# A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma

> **NCT07053332** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Esophagogastric Junction/Gastric Adenocarcinoma

## Interventions

- **DRUG:** PD-1/CTLA-4 combination antibody with low-dose radiotherapy

## Key facts

- **NCT ID:** NCT07053332
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2027-12
- **Final completion:** 2029-08-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07053332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07053332, "A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT07053332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*